1. Rotrosen J; Stanley M; Lautin A; Wazer D; Gershon S; Discrimination of functionally heterogeneous receptor subpopulations: antipsychotic and antidopaminergic properties of metoclopramide [proceedings]  Psychopharmacol Bull, 1981 Jan, 17:1, 110-3
  2. Stanley M; Lautin A; Rotrosen J; Gershon S; Kleinberg D; Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models. Psychopharmacology (Berl), 1980, 71:3, 219-25
  3. Doongaji DR; Desai AB; Satoskar RS; Metoclopramide in schizophrenia (an open study). J Postgrad Med, 1986 Jul, 32:3, 139-45
  4. Stanley M; Wilk S; Striatal DOPAC elevation predicts antipsychotic efficacy of metoclopramide. Life Sci, 1979 May, 24:20, 1907-12
  5. Costall B; Naylor RJ; A comparison of the abilities of typical neuroleptic agents and of thioridazine, clozapine, sulpiride and metoclopramide to antagonise the hyperactivity induced by dopamine applied intracerebrally to areas of the extrapyramidal and mesolimbic systems. Eur J Pharmacol, 1976 Nov, 40:1, 9-19 
  6. Herman ZS; Huzarska M; Chronic treatment with atypical neuroleptics sulpiride and metoclopramide increases striatal enkephalins in rat brain. Pol J Pharmacol, 1993 Sep, 45:5-6, 493-502 
  7. Blackburn JR; Phillips AG; Enhancement of freezing behaviour by metoclopramide: implications for neuroleptic-induced avoidance deficits. Pharmacol Biochem Behav, 1990 Mar, 35:3, 685-91